Skip to main content
SpringerLink
Log in

Adagrasib: First Approval

  • AdisInsight Report
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

Adagrasib (KRAZATI™) is an orally available, potent, irreversible, small molecule inhibitor of KRAS G12C mutant isoform being developed by Mirati Therapeutics for the treatment of solid tumours harbouring KRAS G12C oncogenic driver mutation, including non-small cell lung cancer (NSCLC) and colorectal cancer (CRC). Adagrasib covalently binds to the mutant cysteine in KRAS G12C and locks the mutant KRAS protein in its inactive state, thereby preventing downstream signalling without affecting wild-type KRAS protein. In December 2022, adagrasib received its first approval in the USA for the treatment of adults with KRAS G12C-mutated locally advanced or metastatic NSCLC (as determined by an FDA approved test) who have received ≥ 1 prior systemic therapy. It was approved under accelerated approval based on objective response rate and duration of response, and its continued approval for this indication may be contingent upon verification and description of a clinical benefit in a confirmatory trial(s). The drug is under regulatory review for NSCLC in the European Union and is in development for CRC in the US. Clinical studies of adagrasib in solid tumours, including CRC, are underway in several countries. This article summarizes the milestones in the development of adagrasib leading to this first approval for KRAS G12C-mutated locally advanced or metastatic NSCLC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Huang L, Guo Z, Wang F, et al. KRAS mutation: from undruggable to druggable in cancer. Signal Transduct Target Ther. 2021;6(1):386.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Murciano-Goroff YR, Lito P. The KRYSTAL-1 study of adagrasib—a new trial for KRAS(G12C)-mutated non-small-cell lung cancer. Nat Rev Clin Oncol. 2022;19(11):677–8.

    Article  CAS  PubMed  Google Scholar 

  3. Passaro A, Peters S. Setting the benchmark for KRASG12C-mutated NSCLC. N Engl J Med. 2022;387(2):180–3.

    Article  PubMed  Google Scholar 

  4. Parikh K, Banna G, Liu SV, et al. Drugging KRAS: current perspectives and state-of-art review. J Hematol Oncol. 2022;15(1):152.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. US FDA. FDA grants accelerated approval to adagrasib for KRAS G12C-mutated NSCLC [media release]. 12 Dec 2022. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-adagrasib-kras-g12c-mutated-nsclc.

  6. Mirati Therapeutics I. KRAZATI™ (adagrasib): US prescribing information. 2022. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/216340s000lbl.pdf. Accessed 9 Jan 2023.

  7. European Medicines Agency. Adagrasib: EMA submission. 2022. https://www.ema.europa.eu. Accessed 9 Jan 2023.

  8. Mirati Therapeutics. Mirati announces adagrasib (KRAZATI™) receives breakthrough therapy designation from FDA for patients with advanced, KRAS-mutated colorectal cancer and NEJM publishes phase 1b/2 data from adagrasib with or without cetuximab in colorectal cancer [media release]. 21 Dec 2022. http://www.mirati.com.

  9. Mirati Therapeutics. Mirati announces clinical collaboration to evaluate MRTX849 in combination with SHP2 inhibitor TNO155 [media release]. 9 Jul 2019. https://ir.mirati.com/press-releases/default.aspx.

  10. Boehringer Ingelheim, Mirati Therapeutics. Boehringer Ingelheim and Mirati Therapeutics announce clinical collaboration to study Bi 1701963, a Sos1::pan-Kras inhibitor in combination with Mrtx849, a Kras G12c selective inhibitor [media release]. 17 Sep 2020. https://ir.mirati.com/press-releases/default.aspx.

  11. Resolution Bioscience. Resolution Bioscience announces companion diagnostic collaboration with Mirati Therapeutics [media release]. 11 Jan 2021. https://www.resolutionbio.com.

  12. Mirati Therapeutics. Mirati announces IND clearance by U.S. FDA enabling phase 1 initiation for first-in-class oral KRASG12D selective inhibitor, MRTX1133 [media release]. 19 Jan 2023. https://www.prnewswire.com.

  13. Mirati Therapeutics. MD Anderson and Mirati Therapeutics announce KRAS strategic research and development collaboration In solid tumors [media release]. 10 Feb 2021. https://ir.mirati.com/press-releases/default.aspx.

  14. Qiagen. QIAGEN partners with Mirati Therapeutics Inc. to develop KRASG12C companion diagnostic for non-small cell lung cancer (NSCLC) [media release]. 25 May 2021. https://corporate.qiagen.com/English/newsroom/press-releases/.

  15. Mirati Therapeutics. Mirati Therapeutics and Zai Lab enter into a collaboration to develop and commercialize adagrasib in Greater China [media release]. 1 Jun 2021. https://ir.mirati.com/press-releases/default.aspx.

  16. Mirati Therapeutics. Mirati Therapeutics to collaborate with Sanofi on phase 1/2 study evaluating combination of adagrasib with a SHP2 Inhibitor in KRAS G12C-mutated lung cancer [media release]. 7 Oct 2021. https://ir.mirati.com/press-releases/default.aspx.

  17. Mirati Therapeutics. Mirati Therapeutics and Verastem Oncology partner to evaluate adagrasib in combination with VS-6766 in KRASG12C-mutant non-small cell lung cancer [media release]. 22 Nov 2021. https://ir.mirati.com/press-releases/default.aspx.

  18. Mirati Therapeutics, Aadi Bioscience. Mirati Therapeutics and Aadi Bioscience partner to evaluate the combination of adagrasib with nab-sirolimus in patients with advanced non-small cell lung cancer and other solid tumors with a KRAS[G12C] mutation [media release]. 12 Oct 2022. https://ir.mirati.com/press-releases/default.aspx.

  19. Incyte Corporation, Mirati Therapeutics. Incyte and Mirati Therapeutics enter into clinical trial collaboration and supply agreement to evaluate INCB99280 and adagrasib in patients with KRASG12C-mutated solid tumors [media release]. 2022. https://ir.mirati.com/press-releases/default.aspx.

  20. Fell JB, Fischer JP, Baer BR, et al. Discovery of tetrahydropyridopyrimidines as irreversible covalent inhibitors of KRAS-G12C with in vivo activity. ACS Med Chem Lett. 2018;9(12):1230–4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Hallin J, Engstrom LD, Hargis L, et al. The KRAS(G12C) inhibitor MRTX849 provides insight toward therapeutic susceptibility of KRAS-mutant cancers in mouse models and patients. Cancer Discov. 2020;10(1):54–71.

    Article  CAS  PubMed  Google Scholar 

  22. Briere DM, Li S, Calinisan A, et al. The KRAS(G12C) inhibitor MRTX849 reconditions the tumor immune microenvironment and sensitizes tumors to checkpoint inhibitor therapy. Mol Cancer Ther. 2021;20(6):975–85.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Hallin J, Engstrom L, Hargis L, et al. Effects of adagrasib on oncogenic signaling, immune cell regulation and biomarkers of response in preclinical and preliminary clinical analyses [abstract no. 37 plus poster]. In: Fourth RAS Initiative symposium 2022. 2022.

  24. Sabari JK, Velcheti V, Shimizu K, et al. Activity of adagrasib (MRTX849) in brain metastases: preclinical models and clinical data from patients with KRASG12C-mutant non-small cell lung cancer. Clin Cancer Res. 2022;28(15):3318–28.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Awad MM, Liu S, Rybkin II, et al. Acquired resistance to KRAS(G12C) inhibition in cancer. N Engl J Med. 2021;384(25):2382–93.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Koga T, Suda K, Fujino T, et al. KRAS secondary mutations that confer acquired resistance to KRAS G12C inhibitors, sotorasib and adagrasib, and overcoming strategies: insights from in vitro experiments. J Thorac Oncol. 2021;16(8):1321–32.

    Article  CAS  PubMed  Google Scholar 

  27. Hansen RJ, Horton S, Wiese J, et al. Detection of KRAS amplification on extrachromosomal DNA (ecDNA) upon acquired resistance to KRASG12C inhibitors [abstract no. LBA005]. Mol Cancer Ther. 2021;20(12 Suppl):LBA005.

    Article  Google Scholar 

  28. Zhang Y, Li C, Xia C, et al. Adagrasib, a KRAS G12C inhibitor, reverses the multidrug resistance mediated by ABCB1 in vitro and in vivo. Cell Commun Signal. 2022;20(1):142.

    Article  PubMed  PubMed Central  Google Scholar 

  29. Ou SHI, Jänne PA, Leal TA, et al. First-in-human phase I/IB dose-finding study of adagrasib (MRTX849) in patients with advanced KRASG12C solid tumors (KRYSTAL-1). J Clin Oncol. 2022;40(23):2530–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Jänne PA, Riely GJ, Gadgeel SM, et al. Adagrasib in non-small-cell lung cancer harboring a KRASG12C mutation. N Engl J Med. 2022;387(2):120–31.

    Article  PubMed  Google Scholar 

  31. Jänne PA, Smit EF, de Marinis F, et al. Preliminary safety and efficacy of adagrasib with pembrolizumab in treatment-naïve patients with advanced non-small cell lung cancer (NSCLC) harboring a KRASG12C mutation [abstract no. Abstr. LBA4 plus oral presentation]. In: ESMO immuno-oncology congress. 2022.

  32. Yaeger R, Weiss J, Pelster MS, et al. Adagrasib with or without cetuximab in colorectal cancer with nutated KRAS G12C. N Engl J Med. 2023;388(1):44–54.

    Article  CAS  PubMed  Google Scholar 

  33. Bekaii-Saab TS, Spira AI, Yaeger R, et al. KRYSTAL-1: updated activity and safety of adagrasib (MRTX849) in patients (Pts) with unresectable or metastatic pancreatic cancer (PDAC) and other gastrointestinal (GI) tumors harboring a KRASG12C mutation. [abstract no. 519 plus oral presentation]. J Clin Oncol. 2022;40(4).

  34. Zhang J, Leventakos K, Leal TA, et al. Additional practice-informing adverse event patterns and management in the KRYSTAL-1 phase II study of adagrasib (MRTX849) in patients with KRASG12C-mutated NSCLC [abstract no. 1133P]. Ann Oncol. 2022;33(Suppl 7):S1069.

    Google Scholar 

  35. Qiagen. therascreen® KRAS RGQPCR kit instructions for use(Handbook). 2021. https://www.accessdata.fda.gov/cdrh_docs/pdf11/P110027S012C.pdf. Accessed 13 Jan 2023.

  36. Resolution Bioscience. Agilent Resolution ctDx FIRST technical information. 2022. https://www.accessdata.fda.gov/cdrh_docs/pdf21/P210040C.pdf. Accessed 13 Jan 2023.

  37. Leventakos K, Jänne PA, Johnson ML, et al. Clinical validation of plasma cell-free DNA (cfDNA) sequencing in a phase 2 cohort of the KRYSTAL-1 study of adagrasib in patients with KRASG12C-mutated NSCLC [oral presentation]. In: 4th annual ISLB congress. 2022.

  38. Mok TSK, Lawler WE, Shum MK, et al. KRYSTAL-12: A randomized phase 3 study of adagrasib (MRTX849) versus docetaxel in patients (pts) with previously treated non-small-cell lung cancer (NSCLC) with KRASG12C mutation [abstract no. TPS9129 plus poster]. J Clin Oncol. 2021;39(15).

  39. Tabernero J, Bendell J, Corcoran R, et al. KRYSTAL-10: a randomized phase 3 study of adagrasib (MRTX849) in combination with cetuximab vs chemotherapy in patients with previously treated advanced colorectal cancer with KRASG12C mutation [abstract no. P-71 plus poster]. Ann Oncol. 2021;32(Suppl 3):S121-S.

    Article  Google Scholar 

  40. Scott SC, Hu C, Smith K, et al. Phase 2 trial of neoadjuvant KRASG12C directed therapy with adagrasib (MRTX849) with or without nivolumab in resectable NSCLC (Neo-KAN) [abstract no. EP0204-007]. J Thorac Oncol. 2022;17(9):S235-S.

    Article  Google Scholar 

  41. Sabari JK, Park H, Tolcher AW, et al. KRYSTAL-2: a phase I/II trial of adagrasib (MRTX849) in combination with TNO155 in patients with advanced solid tumors with KRAS G12C mutation [abstract no. TPS146]. J Clin Oncol. 2021;39(3):146.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Springer Nature, Mairangi Bay, Private Bag 65901, Auckland, 0754, New Zealand

    Sohita Dhillon

Authors
  1. Sohita Dhillon
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sohita Dhillon.

Ethics declarations

Funding

The preparation of this review was not supported by any external funding.

Authorship and conflict of interest

During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Sohita Dhillon is a contracted employee of Adis International Ltd/Springer Nature and declares no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.

Ethics approval, consent to participate, consent to publish, availability of data and material, code availability

Not applicable.

Additional information

This profile has been extracted and modified from the AdisInsight database. AdisInsight tracks drug development worldwide through the entire development process, from discovery, through pre-clinical and clinical studies to market launch and beyond.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file1 (PDF 204 KB)

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Dhillon, S. Adagrasib: First Approval. Drugs 83, 275–285 (2023). https://doi.org/10.1007/s40265-023-01839-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40265-023-01839-y

Search

Navigation